Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Operations (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Cash from Operations for 9 consecutive years, with 26435000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 63.15% to 26435000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 177231000.0 through Dec 2025, up 7.47% year-over-year, with the annual reading at 177231000.0 for FY2025, 7.47% up from the prior year.
  • Cash from Operations hit 26435000.0 in Q4 2025 for Sutro Biopharma, up from 38189000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 65854000.0 in Q3 2022 to a low of 71738000.0 in Q4 2024.
  • Historically, Cash from Operations has averaged 27925850.0 across 5 years, with a median of 30812500.0 in 2021.
  • Biggest five-year swings in Cash from Operations: soared 369.83% in 2022 and later plummeted 879.13% in 2023.
  • Year by year, Cash from Operations stood at 21580000.0 in 2021, then decreased by 10.58% to 23864000.0 in 2022, then soared by 158.97% to 14072000.0 in 2023, then crashed by 609.79% to 71738000.0 in 2024, then surged by 63.15% to 26435000.0 in 2025.
  • Business Quant data shows Cash from Operations for STRO at 26435000.0 in Q4 2025, 38189000.0 in Q3 2025, and 44724000.0 in Q2 2025.